FDA approves AstraZeneca, Daiichi Sankyo's Datroway in EGFR-mutated lung cancer
The FDA on Monday approved AstraZeneca and Daiichi Sankyo’s TROP2-targeting drug Datroway in a new lung cancer indication, broadening the amount of patients for what the company hopes is their next big blockbuster. Datroway is ...
The FDA on Monday approved AstraZeneca and Daiichi Sankyo’s TROP2-targeting drug Datroway in a new lung cancer indication, broadening the amount of patients for what the company hopes is their next big blockbuster.
Datroway is ...
